Topic

ede

15 articles

Dubai recalls in 5 steps: what pharmacies and food operators must do when products are unsafe

A practical guide to UAE food and product recalls. Learn who acts, what records matter, and what Dubai operators should check first.

7 Oct 2026 · 3 min read

Dubai recalls in 5 steps: what pharmacies and food operators must do when products are unsafe

EDE approves MIMRYLO for polycythemia vera, UAE becomes 2nd global market

The UAE cleared rusfertide for adults with polycythemia vera. Clinics and insurers now need a pathway for eligibility, monitoring and reimbursement.

2 Oct 2026 · 3 min read

EDE approves MIMRYLO for polycythemia vera, UAE becomes 2nd global market

EDE approves MIMRYLO for rare blood disorder as UAE becomes 2nd global market

The UAE cleared MIMRYLO for adults with polycythemia vera. Clinics, insurers and patients now face formulary, access and monitoring decisions.

30 Sept 2026 · 3 min read

EDE approves MIMRYLO for rare blood disorder as UAE becomes 2nd global market

3 checks Dubai patients should make after the NDLEA-NDEA drug-trafficking pact

Patients with controlled medicines should expect tighter document checks. Here is what to prepare before travel or pharmacy pickup in the UAE.

29 Sept 2026 · 3 min read

3 checks Dubai patients should make after the NDLEA-NDEA drug-trafficking pact

EDE visits 2 Korean CGT firms as UAE clinics weigh AED 1.4m-plus therapies

UAE regulators met Biosolution and Helixmith in Seoul. Clinics, insurers and patients should watch pricing, eligibility and approval pathways.

10 Sept 2026 · 3 min read

EDE visits 2 Korean CGT firms as UAE clinics weigh AED 1.4m-plus therapies

EDE meets 2 Korean CGT firms as UAE weighs cell and gene therapy access

EDE visited Biosolution and Helixmith in Seoul. UAE operators should track approvals, referral controls and payer exposure for CGT.

10 Sept 2026 · 3 min read

EDE meets 2 Korean CGT firms as UAE weighs cell and gene therapy access

EDE’s 9 September Korea visit puts CGT pathway on UAE pharmacy agenda

EDE met Biosolution and Helixmith on CGT cooperation. UAE clinics, insurers and pharmacies should watch approval, access and referral pathways.

9 Sept 2026 · 3 min read

EDE’s 9 September Korea visit puts CGT pathway on UAE pharmacy agenda

Breaking

5 recall numbers Dubai pharmacies and food operators need before a contaminated product reaches patients

A practical UAE guide to contaminated food and product recalls: who acts, what to freeze, and where penalties start.

27 Aug 2026 · 3 min read

5 recall numbers Dubai pharmacies and food operators need before a contaminated product reaches patients

EDE approves once-daily Rinvoq for UAE vitiligo patients aged 12+

The UAE is the first market to approve oral Rinvoq for non-segmental vitiligo. Clinics and insurers now face pricing, eligibility and monitoring questions.

23 Aug 2026 · 3 min read

EDE approves once-daily Rinvoq for UAE vitiligo patients aged 12+

EDE approves once-daily RINVOQ for vitiligo patients aged 12+ in UAE

The UAE is first to approve oral RINVOQ for eligible non-segmental vitiligo. Clinics and insurers now need protocols, pricing checks and prior authorisation rules.

21 Aug 2026 · 3 min read

EDE approves once-daily RINVOQ for vitiligo patients aged 12+ in UAE

EDE approves Rinvoq for vitiligo patients aged 12+ as UAE clinics face AED 5,789 monthly drug cost

The UAE approved once-daily Rinvoq for non-segmental vitiligo. Clinics, insurers and patients now face eligibility, monitoring and coverage decisions.

21 Aug 2026 · 3 min read

EDE approves Rinvoq for vitiligo patients aged 12+ as UAE clinics face AED 5,789 monthly drug cost

UAE approves Rinvoq for vitiligo in patients 12+ as first oral systemic option

EDE approved once-daily Rinvoq for eligible non-segmental vitiligo patients. Clinics need prescribing, price and insurance checks.

20 Aug 2026 · 3 min read

UAE approves Rinvoq for vitiligo in patients 12+ as first oral systemic option

UAE approves Rinvoq for vitiligo patients aged 12+, creating first country-level oral licence

Rinvoq is now approved in the UAE for eligible non-segmental vitiligo patients. Clinics and insurers must prepare for systemic therapy demand.

18 Aug 2026 · 3 min read

UAE approves Rinvoq for vitiligo patients aged 12+, creating first country-level oral licence

Regulatory & Policy

EDE makes UAE 3rd global market for Jascayd pulmonary fibrosis drug

EDE approved Jascayd for adult IPF and PPF patients on 19 June 2026, putting UAE providers on the clock for formulary, pathway and payer decisions.

20 Jun 2026 · 3 min read

EDE makes UAE 3rd global market for Jascayd pulmonary fibrosis drug

Regulatory & Policy

EDE clears AstraZeneca Etcamah after 55% PFS risk cut, ahead of FDA decision

EDE’s Etcamah approval gives UAE oncology leaders a 2026 formulary and testing decision: whether to fund serial ESR1 monitoring before radiographic progression.

11 Jun 2026 · 3 min read

EDE clears AstraZeneca Etcamah after 55% PFS risk cut, ahead of FDA decision